|
Market Cap (5-Jun) $102,067,456 (1,050th) |
Close (30-Jun) $0.062 |
Volume (30-Jun) 526,676 |
Shortsold (26-May) 683,172 (0.11%) (444th) |
|
52w High $0.67 |
52w Low $0.165 |
P/E 10.78 |
EPS -0.03 |
DXB released this announcement to the ASX on 27 July 2021, 8:25. The announcement is marked as price sensitive, and is 8 page(s) in length and 511.42kb in size.
You can view all announcements from DXB and see how they appear on a price chart on the announcements page.
At the date of this announcement, DXB was 0.027% short sold according to ASIC data. It was ranked the 550th most shorted stock on the ASX. It is now ranked as the 444th most shorted stock on the ASX with 0.114% of total shares short sold as of the latest reported data (26 May 2026).
| Other Recent Announcements from DXB | |
|---|---|
| Application for quotation of securities - DXB | 29 June 2023, 9:01 |
| Application for quotation of securities - DXB | 29 June 2023, 9:00 |
| Application for quotation of securities - DXB | 29 June 2023, 8:59 |
| Quarterly Appendix 4C and Activities Report | 27 July 2021, 8:25 |
| FDA Confirms Phase 3 Study Design in FSGS Kidney Disease | 19 July 2021, 9:21 |
| Dimerix Receives Innovation Passport and ILAP Designation | 7 June 2021, 9:20 |
| Dimerix Confirms Phase 3 FSGS Study Design With EMA | 3 June 2021, 9:41 |
You must be logged in to post a reply.
Dimerix 